Zenbexus savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Zenbexus

We didn’t find one.

Ask your pharmacy for Zenbexus’s cash price, and one or two other pharmacies too.
Zenbexus’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bristol Myers Squibb Patient Assistance Foundation (BMSPAF). Or call 1-800-736-0003.

See if you qualify

Compare every option

Brand nameZenbexus

Authorized genericiberdomide

Regular genericiberdomide

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Zenbexus?

The original

–

Brand nameThe maker’s card

BMS Access Support Co-Pay Assistance Program

Savings card from Bristol Myers Squibb

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

Or call 1-800-861-0048.

In the maker’s words

“Eligible patients may pay as little as $0 per one-month supply, subject to a maximum benefit.”

From the maker’s offer on bmsaccesssupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Zenbexus itself, from the same company, sold without the brand name, and usually for less. For now Zenbexus is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Multiple myeloma

What the FDA label says

ZENBEXUS is a cereblon-modulating protein degrader indicated in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Source: the FDA label for Zenbexus (E.R. Squibb & Sons, L.L.C.), August 13, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/zenbexus/